Lycia Therapeutics, South San Francisco, CA, Hybrid
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 19 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In June, 2026, Lycia Therapeutics completed a $75 million Series D financing to advance its pipeline of LYTAC extracellular protein degraders into the clinic. Lycia is headquartered in South San Francisco.
Visit for more information.
Lycia Therapeutics is seeking a highly motivated and experienced Senior Director, Controller to lead the company’s accounting and financial reporting functions during a pivotal period of growth. Reporting to the SVP, Finance, this leader will own the integrity of Lycia’s financial statements, direct the monthly and quarterly close process, lead the annual audit, and ensure the company’s accounting infrastructure scales with its ambitions. This is a high-visibility role that partners closely with senior leadership and the audit committee on complex accounting matters and cross-functional financial operations.
The expected base salary range for this role is $265,000-$290,000. We encourage candidates of all levels to apply as there is often flexibility on job title and responsibilities. Compensation will be based on a variety of factors, including experience, qualifications, and internal equity. Lycia offers a competitive employment package that includes an annual bonus, equity, and a generous benefits package.
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Lycia and other biotech companies have recently noticed an increase in email and social media scams targeting job candidates in our industry. Please note Lycia will post any legitimate job openings directly on our website or through our recruitment partner, Lever. If you wish to verify the legitimacy of a job opening, you may contact us.
We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses and identifying potential inconsistencies or verification signals in application materials based on available information. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.
At Lycia, we aim to eliminate the source of disease using the power of extracellular protein degradation. Our novel LYTAC therapeutics are designed to bind and remove disease-causing extracellular proteins by directing them into the cell for degradation via the lysosome. Focused initially on autoimmune and inflammatory diseases, our platform addresses gaps in targeting proteins outside the cell, offering new hope to patients who urgently need better options.
View company profile →